Immunomodulatory actions of vitamin D metabolites and their potential relevance to human lung disease

Current Respiratory Medicine Reviews

Volumn 7, Issue 6, 2011, Pages 444-453

  Coussens, Anna K ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

125 dihydroxyvitamin D; Autoimmunity; Cytokine; Dendritic cell; Immunomodulation; Infection; Macrophage; T cell; T reg

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIFEDIOL; CYTOCHROME P450; ERGOCALCIFEROL; RETINOIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

ALLELE; ANTIMICROBIAL ACTIVITY; ASTHMA; B LYMPHOCYTE; BINDING AFFINITY; CANCER SURVIVAL; CATABOLISM; CELL FUNCTION; CELL MATURATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE EXACERBATION; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG DISEASE; LUNG FUNCTION; LUNG TUBERCULOSIS; MACROPHAGE; MAST CELL; MONOCYTE; NONHUMAN; PHAGOCYTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE;

EID: 81155126256     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/157339811798072577     Document Type: Review

References (129)

1. Wang TT, Tavera-Mendoza LE, Laperriere D, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19(11): 2685-2695.
2. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 1981; 305(8): 440-443.
3. Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin Ddependent mechanism. J Clin Invest 2007; 117(3): 803-811.
4. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311(5768): 1770-1773.
5. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85(6): 1586-1591.
6. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86(3): 645-651.
7. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91(5): 1255-1260.
8. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83(4): 754-759.
9. Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent infections: a sub-study of a randomized placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2007.
10. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 2009; 179(9): 843-850.
11. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377(9761): 242-250.
12. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci 2006; 1079: 310-312.
13. Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169(6): 626-632.
14. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-281.
15. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1): 53-58.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911-1830.
17. Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 1971; 50(10): 2159-2167.
18. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88(2): 582S-586S.
19. Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW. Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med 1985; 105(2): 239-246.
20. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest 2005; 128(6): 3792-3798.
21. Porojnicu AC, Robsahm TE, Dahlback A, et al. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer 2007; 55(3): 263-270.
22. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 2009; 29(9): 3699-3704.
23. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010.
24. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008; 37(1): 113-119.
25. Laaksi I, Ruohola JP, Tuohimaa P, et al. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 2007; 86(3): 714-717.
26. Hughes DA, Norton R, Vitamin D and respiratory health. Clin Exp Immunol 2009; 158(1): 20-25.
27. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89(5): 552-572.
28. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84(4): 694-697.
29. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 Is as Effective as Vitamin D3 in Maintaining Circulating Concentrations of 25-Hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93(3): 677-681.
30. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376(9736): 180-188.
31. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92(2): 183-188.
32. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005; 77(1): 15-22.
33. Wjst M, Altmuller J, Faus-Kessler T, Braig C, Bahnweg M, Andre E. Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res 2006; 7: 60.
34. Martineau AR, Leandro AC, Anderson ST, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. Eur Respir J 2010; 35(5): 1106-1112.
35. Lu M, Yang B, Cai YY. [The relationship between vitamin D binding protein gene polymorphism and chronic obstructive pulmonary disease]. Zhonghua Nei Ke Za Zhi 2004; 43(2): 117-120.
36. Orton SM, Morris AP, Herrera BM, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008; 88(2): 441-447.
37. Ogunkolade BW, Boucher BJ, Prahl JM, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002; 51(7): 2294-2300.
38. Andraos C, Koorsen G, Knight JC, Bornman L. Vitamin D receptor gene methylation is associated with ethnicity, tuberculosis, and TaqI polymorphism. Hum Immunol 2011; 72(3): 262-268.
39. Song Y, Qi H, Wu C. Effect of 1,25-(OH)2D3 (a vitamin D analogue) on passively sensitized human airway smooth muscle cells. Respirology 2007; 12(4): 486-494.
40. Dogan I, Onen HI, Yurdakul AS, et al. Polymorphisms in the vitamin D receptor gene and risk of lung cancer. Med Sci Monit 2009; 15(8): BR232-BR242.
41. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. Vitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood. J Infect Dis 2008; 197(5): 676-680.
42. Hopkinson NS, Li KW, Kehoe A, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr 2008; 87(2): 385-390.
43. Ito I, Nagai S, Hoshino Y, et al. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004; 125(1): 63-70.
44. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355(9204): 618-621.
45. Liu W, Cao WC, Zhang CY, et al. VDR and NRAMP1 gene polymorphisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control study. Int J Tuberc Lung Dis 2004; 8(4): 428-434.
46. Selvaraj P, Chandra G, Jawahar MS, Rani MV, Rajeshwari DN, Narayanan PR. Regulatory role of vitamin D receptor gene variants of Bsm I, Apa I, Taq I, and Fok I polymorphisms on macrophage phagocytosis and lymphoproliferative response to mycobacterium tuberculosis antigen in pulmonary tuberculosis. J Clin Immunol 2004; 24(5): 523-532.
47. Roth DE, Soto G, Arenas F, et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J Infect Dis 2004; 190(5): 920-927.
48. Babb C, van der Merwe L, Beyers N, et al. Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis (Edinb) 2007; 87(4): 295-302.
49. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981; 78(8): 4990-4994.
50. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98(2): 391-398.
51. Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985; 161(4): 755-765.
52. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983; 72(5): 1856-1860.
53. Fuss M, Pepersack T, Gillet C, Karmali R, Corvilain J. Calcium and vitamin D metabolism in granulomatous diseases. Clin Rheumatol 1992; 11(1): 28-36.
54. Dusso AS, Kamimura S, Gallieni M, et al. gamma-Interferoninduced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997; 82(7): 2222-2232.
55. Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 2002; 22(8): 2777-2787.
56. Krutzik SR, Hewison M, Liu PT, et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 2008; 181(10): 7115-7120.
57. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179(3): 1634-1647.
58. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007; 8(3): 285-293.
59. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003; 102(9): 3314-3316.
60. Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zugel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 2010; 118(3): 142-150.
61. Shalita-Chesner M, Koren R, Mekori YA, et al. 1,25-Dihydroxyvitamin D3 enhances degranulation of mast cells. Mol Cell Endocrinol 1998; 142(1-2): 49-55.
62. Gottfried E, Rehli M, Hahn J, Holler E, Andreesen R, Kreutz M. Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun 2006; 349(1): 209-213.
63. Lundgren S, Carling T, Hjalm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997; 45(3): 383-392.
64. Chun RF, Lauridsen AL, Suon L, et al. Vitamin D-Binding Protein Directs Monocyte Responses to 25-Hydroxy- and 1,25-Dihydroxyvitamin D. J Clin Endocrinol Metab 2010; 95(7): 3368-3376.
65. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008; 149(7): 3656-3667.
66. Van Baelen H, Bouillon R, De Moor P. Vitamin D-binding protein (Gc-globulin) binds actin. J Biol Chem 1980; 255(6): 2270-2272.
67. Yamamoto N, Homma S, Millman I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 1991; 147(1): 273-280.
68. Kew RR, Webster RO. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest 1988; 82(1): 364-369.
69. Piquette CA, Robinson-Hill R, Webster RO. Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin. J Leukoc Biol 1994; 55(3): 349-354.
70. Dahl B, Schiodt FV, Kiaer T, Ott P, Bondesen S, Tygstrup N. Serum Gc-globulin in the early course of multiple trauma. Crit Care Med 1998; 26(2): 285-289.
71. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28(6): 738-745.
72. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372(1-2): 33-42.
73. Kanan RM, Cook DB, Datta HK. Lectin immunoassay for macrophage-activating factor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence for noninducible generation of Gc-MAF. Clin Chem 2000; 46(3): 412-414.
74. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294(5548): 1866-1870.
75. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16(2): 200-257.
76. Uchida M, Ozono K, Pike JW. Activation of the human osteocalcin gene by 24R,25-dihydroxyvitamin D3 occurs through the vitamin D receptor and the vitamin D-responsive element. J Bone Miner Res 1994; 9(12): 1981-1987.
77. Lou YR, Molnar F, Perakyla M, et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol; 118(3): 162-170.
78. Crowle AJ, Ross EJ. Comparative abilities of various metabolites of vitamin D to protect cultured human macrophages against tubercle bacilli. J Leukoc Biol 1990; 47(6): 545-550.
79. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57(1): 159-163.
80. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8(4): 174-179.
81. Imazeki I, Matsuzaki J, Tsuji K, Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res 2006; 27(1): 1-9.
82. Anand PK, Kaul D. Vitamin D3-dependent pathway regulates TACO gene transcription. Biochem Biophys Res Commun 2003; 310(3): 876-877.
83. Anand PK, Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol Lett 2005; 250(1): 137-144.
84. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE. 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptorphosphatidylinositol 3-kinase signaling complex. J Exp Med 1999; 190(11): 1583-1594.
85. Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem 2001; 276(38): 35482-35493.
86. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998; 66(11): 5314-5321.
87. Fratti RA, Backer JM, Gruenberg J, Corvera S, Deretic V. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 2001; 154(3): 631-644.
88. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-{gamma}- and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-37. J Immunol 2007; 178(11): 7190-7198.
89. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11(4): 344-349.
90. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 downregulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36(2): 361-370.
91. Li C, Wang Y, Gao L, et al. Expression of toll-like receptors 2 and 4 and CD14 during differentiation of HL-60 cells induced by phorbol 12-myristate 13-acetate and 1 alpha, 25-dihydroxy-vitamin D(3). Cell Growth Differ 2002; 13(1): 27-38.
92. Sorensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97(12): 3951-3959.
93. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134(6): 1129-1140.
94. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008; 181(10): 7090-7099.
95. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170(5): 2274-2278.
96. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96(9): 3086-3093.
97. Rivas-Santiago B, Hernandez-Pando R, Carranza C, et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008; 76(3): 935-941.
98. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 2006; 38(1): 3-5.
99. Gombart AF, Saito T, Koeffler HP. Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin Dmediated innate immune response in humans and primates. BMC Genomics 2009; 10: 321.
100. Neville F, Cahuzac M, Konovalov O, et al. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J 2006; 90(4): 1275-1287.
101. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6(3): 231-243.
102. Hart PD, Young MR, Gordon AH, Sullivan KH. Inhibition of phagosome-lysosome fusion in macrophages by certain mycobacteria can be explained by inhibition of lysosomal movements observed after phagocytosis. J Exp Med 1987; 166(4): 933-946.
103. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010; 285(4): 2227-2231.
104. Liu PT, Schenk M, Walker VP, et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 2009; 4(6): e5810.
105. Gauzzi MC, Purificato C, Donato K, et al. Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 2005; 174(1): 270-276.
106. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164(5): 2405-2411.
107. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a proinflammatory profile. 1,25-Dihydroxyvitamin D(3) works as antiinflammatory. Diabetes Res Clin Pract 2007; 77(1): 47-57.
108. Rook GA, Taverne J, Leveton C, Steele J. The role of gammainterferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62(2): 229-234.
109. Helming L, Bose J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106(13): 4351-4358.
110. Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M. Interactions of 1 alpha,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J Allergy Clin Immunol 2005; 116(3): 683-689.
111. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183(9): 5458-5467.
112. Smolders J, Menheere P, Thewissen M, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol 2010; 121(1-2): 243-246.
113. Akbari O, Stock P, DeKruyff RH, Umetsu DT. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 2003; 15(6): 627-633.
114. Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 2002; 168(3): 1181-1189.
115. Wolf AJ, Linas B, Trevejo-Nunez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179(4): 2509-2519.
116. Wolf AJ, Desvignes L, Linas B, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008; 205(1): 105-115.
117. Pedersen AW, Holmstrom K, Jensen SS, et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol 2009; 157(1): 48-59.
118. Matsuzaki J, Tsuji T, Zhang Y, et al. 1alpha,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokineconditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation. Cancer Sci 2006; 97(2): 139-147.
119. Szeles L, Keresztes G, Torocsik D, et al. 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 2009; 182(4): 2074-2083.
120. Van Overtvelt L, Lombardi V, Razafindratsita A, et al. IL-10- inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008; 145(2): 152-162.
121. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286(5437): 113-117.
122. Coussens A, Timms PM, Boucher BJ, et al. 1alpha,25-dihydroxyvitamin D inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology 2009; 127(4): 539-548.
123. Elkington PT, Nuttall RK, Boyle JJ, et al. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 2005; 172(12): 1596-1604.
124. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51(3): 306-311.
125. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 2002; 6(8): 713-719.
126. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010; 327(5964): 466-469.
127. Li Y, Zhang Z, Xu Y, Xiong S, Ni W, Chen S. TNF-alpha upregulates matrix metalloproteinase-9 expression and activity in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Huazhong Univ Sci Technolog Med Sci 2006; 26(6): 647-650.
128. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151.
129. Anand SP, Selvaraj P. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin Immunol 2009; 133(1): 126-131.